McKesson, Blue Cross top digital health’s most trusted corporate VCs
Part II in our research examining which corporate venture capitalists you can trust and rely on.
Startups: Know when you’re valuable, know when you’re not – and remember to take notes
If you run a startup, do these three rules resonate?
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Life is sometimes like HBO’s Silicon Valley (unfortunately)
Hard truth: Even the most promising startups are one calamity away from completely shutting down. Self-inflicted wounds are hard to escape from. But there are increasingly a number of options when a competitor, customer or would-be investor puts a company on the brink. Lee Ducker, one of the founders of Lake Whillans, sees the horror […]
A healthcare investing prediction: The world becomes fickle
Hey startup CEO: How will you need to think differently about protecting your assets in a way that allows you to build value in the long term?
Healthcare entrepreneurs trust no one (and that’s why they’re brilliant)
There are plenty of good investors out there, but many will pull a Mr. Hyde act to get what they want from healthcare entrepreneurs.
Read the MedCity News survey on corporate venture capital in healthcare
It's time to know more about corporate venture capital because, unlike traditional venture or angel groups, there's much less insight on corporate VCs and their practices.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Another way to mitigate risk in healthcare venture capital
We all want the 12x, but what happens when you're the 1x - and how do you make sure nothing goes wrong?
How to protect your business in the changing medtech landscape
Last week, I discussed the changing landscape of medtech innovation, and how shifting dynamics in the capital raising process have led young businesses to be more vulnerable to unscrupulous partners and mal-intentioned competitors. This week I will begin discussing how distressed venture funding and litigation finance can be used to help protect these innovating young […]
The changing landscape of medtech innovation
Unfortunately, it is not uncommon for larger corporations to invest in promising healthcare companies, only to take advantage of their position by developing the underlying technology themselves or dispensing with the project so as to avoid cannibalizing sales.
How to raise capital in a difficult situation
Distressed venture finance and litigation finance are relatively new financial products that can help otherwise vulnerable businesses protect themselves. Companies, such as Lake Whillans, that provide these products can help businesses threatened by others' unscrupulous actions.
presented by
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
This entrepreneur nearly lost his company. Here’s how litigation finance helped him fight back
As much as the landscape for biotechnology startups has changed over the last decade, one thing that hasn’t changed is this: Intellectual property is the beating heart of a business.